TY  - CHAP
M1  - Book, Section
TI  - Hodgkin Lymphoma
A1  - Damon, Lloyd E.
A1  - Andreadis, Charalambos Babis
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Key  Clinical  Updates  in  Hodgkin  LymphomaABVD  (doxorubicin,  bleomycin,  vinblastine,  dacarbazine)  chemotherapy  remains  the  standard  first-line  regimen.  The  substitution  of  the  antibody-drug  conjugate  brentuximab  vedotin  for  bleomycin  (AAVD)  has  demonstrated  superior  progression-free  survival  to  ABV  but  no  change  in  overall  survival.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184166362
ER  -